The Journal

All articles

• Lipoprotein(a): The Inherited Cardiovascular Marker Worth Measuring Before You Start a Protocol — Lipoprotein(a) is a largely genetically determined blood marker linked in observational and genetic studies to cardiovascular risk, and it is rarely included in routine panels. This article explains what it is, why a single measurement is usually informative, and how it fits into physician-led baseline screening.
• Irritable Bowel Syndrome and the Gut-Brain Axis: What Peptide Research Suggests About Visceral Sensitivity — Irritable bowel syndrome is a disorder of gut-brain signalling rather than visible tissue damage. This article reviews what preclinical research suggests about neuropeptides, visceral pain and gut motility, and why diagnosis and screening come first.
• Measuring Body Composition in Peptide Therapy: DEXA, Bioimpedance and Waist-to-Height Ratio Compared — Body composition can be assessed using DEXA, bioimpedance and waist measurements, and this article reviews what each method can and cannot measure.
• Ginkgo and Korean Ginseng: What the Research Has Looked At and Who Should Check First — Ginkgo biloba and Korean ginseng extracts are examined in clinical studies, and this article reviews findings and medication questions.
• Dry Eye Disease and Thymosin Beta-4: What Ophthalmic Research Shows About Ocular Surface Repair — Dry eye disease is common in air-conditioned, dusty Gulf environments. Thymosin beta-4 has been studied in topical ophthalmic trials, but the evidence is mixed and does not extend to injected peptide protocols.
• HbA1c, Fasting Glucose and Fasting Insulin: Three Different Views of Your Blood Sugar — Fasting glucose, HbA1c and fasting insulin each describe blood sugar control over a different timeframe, and they can disagree. Here is what each marker measures, why fasting insulin often changes first, and how HOMA-IR brings them together.
• Isotretinoin and Peptide Therapy: What Roaccutane Means for Skin-Repair Protocols — Isotretinoin is one of the most potent prescription medicines in dermatology, and it changes how skin heals, tolerates injections and responds to procedures. This article explains what is known, what is not, and why physician review comes before any peptide protocol.
• Iron Deficiency Without Anaemia: Why a Normal Haemoglobin Can Hide Low Iron Stores — Iron stores can run low long before haemoglobin falls, and the fatigue, poor recovery and reduced training tolerance that follow are easy to misattribute. This article explains how ferritin, transferrin saturation and inflammation markers are read together, who is most at risk, and why iron status is checked before many repair and GH-axis protocols.
• Biotin for Hair, Skin and Nails: What the Evidence Covers and Why High Doses Can Skew Blood Tests — Biotin is a B vitamin involved in normal hair and skin maintenance, yet research in people who are not deficient is limited. High-dose supplements can also interfere with some laboratory assays, so timing around blood tests matters.
• ACL and Knee Ligament Injuries: What Research Shows About Graft Healing and Where Peptides Fit — ACL grafts take many months to remodel into ligament-like tissue, and the knee can feel ready long before the graft is. This article reviews the preclinical peptide research and why structured rehabilitation remains the foundation of recovery.
• IV Vitamins vs Oral Supplements: What Changes When Nutrients Bypass the Gut — Intravenous delivery places vitamins, minerals and fluid directly into the bloodstream, skipping digestion and first-pass metabolism. This article explains what that means for absorption, where the research is clear and where it is not, and when a tablet is the better tool.
• Endometriosis and Peptide Research: What Preclinical Data Shows About Inflammation, Fibrosis and Why Caution Comes First — Endometriosis is a chronic, hormone-sensitive inflammatory condition. This article reviews what preclinical peptide research has examined, where the evidence ends, and why physician screening and gynaecological input come first.
• Stress Fractures in Runners: What Research Shows About Bone Stress Injuries and Where Peptides Fit — Bone stress injuries are a load-management problem first and a healing problem second. This article explains how stress fractures develop, why energy availability and training ramp matter as much as rest, and what preclinical peptide research does and does not show about fracture repair.
• Melatonin and Jet Lag: What the Research Looked At — Melatonin is examined in research on circadian rhythms and time-zone travel, and this article reviews evidence and questions for physician guidance.
• Peptides for skin and recovery: what the evidence says — Peptide studies examine skin biology and recovery-related processes, and this article reviews experimental findings and limitations in human evidence.
• Peptides and weight management in the UAE: what to know — Some prescription medicines used for weight management are peptides. Here is how they fit into medical care, the risks involved, and why supervision matters.
• Peptide Research: What the Evidence Can and Cannot Establish — Peptides are examined across different areas of biomedical research, and this article reviews evidence limitations without promising treatment outcomes.
• Collagen peptides vs prescription peptides: what is the difference? — Collagen powders and prescription peptides share a name but little else. Learn how they differ in purpose, regulation and supervision.
• How a peptide protocol is chosen: the physician-led process — There is no one-size-fits-all peptide protocol. Here is how a physician decides what, if anything, is right for you: consultation, blood tests, review and follow-up.
• Peptides: Risks, Side Effects and Questions for a Physician — Peptide-related risks vary by compound and clinical context, and this article reviews evidence limitations and questions to discuss with a physician.
• Chronic and Diabetic Wounds: What Peptide Research Shows About Stalled Healing — Most wounds heal in a predictable sequence, but in diabetes and poor circulation that sequence can stall. This article explains why, and what preclinical research suggests about peptides and the repair process.
• How to Prepare for a Blood Test: Fasting, Timing, Training and Hydration — What you do in the 48 hours before a blood draw can shift glucose, insulin, lipids, cortisol, ferritin and creatine kinase. A practical guide to fasting windows, morning timing, training rest and hydration so your results reflect your baseline rather than yesterday.
• Muscle Strains and Tears: What Peptide Research Shows About Skeletal Muscle Repair — Peptide research on skeletal tissue repair remains largely preclinical, and this article examines the evidence and its limitations in human care.
• Peptide Prescription Units: Why Clinician Guidance Matters — Peptide prescriptions and product labels may use different units, so interpretation requires guidance from the responsible clinician or pharmacist.
• Zinc as a Food Supplement: Food Sources, Forms, Timing and Upper Limits — Zinc contributes to normal immune function, protein synthesis and skin maintenance, but form, timing and total daily intake all matter. This article covers food sources, how to read a zinc label, and why upper limits deserve attention.
• Acne and Rosacea: What Peptide Research Shows About Sebaceous Inflammation and Skin Barrier Repair — Acne and rosacea are driven by overlapping inflammatory and barrier-related processes rather than surface oil alone. This article reviews what preclinical research suggests about peptides in these pathways, and where the evidence stops.
• Your First IV Drip Session: Screening, the Cannula, Session Length and Aftercare — A first IV session involves clinical screening and nurse-led care, and this article explains assessment, infusion monitoring and aftercare considerations.
• Plantar Fasciitis and Heel Pain: What Peptide Research Suggests About a Stubborn Connective Tissue Problem — Plantar fasciitis is a common cause of heel pain in runners, padel players and people on their feet all day, and it is slow to settle. This article explains the biology of the plantar fascia and what preclinical research suggests about peptides in tendon-like tissue repair.
• Padel Injuries in the UAE: What Peptide Research Shows About Tennis Elbow, Achilles and Rotator Cuff Recovery — Padel has become one of the most-played sports in the UAE, and with it has come a predictable pattern of overuse injuries to the elbow, shoulder and Achilles. This article explains why these tissues break down, what preclinical peptide research suggests about tendon repair, and how a clinician approaches recovery alongside load management.
• Vitamin C and Collagen Formation: What the Nutrient Does — Vitamin C is a required cofactor for the enzymes that build collagen and a water-soluble antioxidant. This article explains the research, food sources, form and timing, and who should check with a doctor first.
• Normal Range vs Optimal Range: How to Read Your Blood Test Results — A result inside the laboratory reference range is not always the same as a result a doctor would call optimal. This article explains how reference ranges are built, why "normal" varies between labs, and how markers such as HbA1c, ferritin, vitamin D and TSH are interpreted in context.
• Hearing Loss and Tinnitus: What Research Shows About Cochlear Repair and Where Peptides Fit — The inner ear repairs poorly, and tinnitus is increasingly understood as a disorder of neural signalling. This article reviews what mechanistic and preclinical research shows, and why formal assessment must come before any adjunct protocol.
• Crohn's Disease and Ulcerative Colitis: What Peptide Research Shows About Gut Inflammation and Mucosal Repair — Inflammatory bowel disease involves chronic immune-driven injury to the gut lining. This article reviews what preclinical research on BPC-157, KPV and thymosin beta-4 suggests, where the evidence stops, and why gastroenterology care remains the foundation.
• Glycation and Skin Ageing: What Advanced Glycation End-Products Do to Collagen and What Peptide Research Suggests — Advanced glycation end-products (AGEs) form when sugars bind irreversibly to collagen and elastin, stiffening the dermal matrix in a process that is separate from UV damage. This article reviews how glycation accelerates skin ageing, how it is measured, and where copper peptide and repair peptide research intersects with it.
• Ashwagandha KSM-66: What the Research Has and Has Not Shown for Stress and Sleep — Ashwagandha extracts are examined in studies of stress and sleep, and this article reviews what trials measured and where evidence remains limited.
• Frozen Shoulder (Adhesive Capsulitis): What Peptide Research Suggests About Inflammation, Fibrosis and Recovery — Frozen shoulder is a fibrotic, inflammatory condition of the joint capsule that can last well over a year. This article reviews what is known about its biology and what preclinical peptide research does and does not suggest.
• Who Should Not Have an IV Drip? Contraindications and Why Medical Screening Comes First — IV vitamin and hydration drips bypass the gut, which is exactly why they are not suitable for everyone. This article explains the main medical reasons a doctor may decline or adjust an IV session, and what the screening process checks before a nurse sets up a line.
• Peptides and Chronic Pain: What Research Shows About Central Sensitisation and Why Persistent Pain Is Not Just Tissue Damage — Persistent pain often outlasts the injury that started it, driven by changes in how the nervous system processes signals. This article reviews what preclinical research suggests about peptides, inflammation and pain signalling, and why clinical screening comes first.
• Injection Site Reactions in Peptide Therapy: What Is Normal, What Is Not, and When to Contact Your Clinician — Mild redness, a small bump or a bruise at a subcutaneous injection site is common and usually self-limiting. This article explains the biology behind local reactions, what a normal timeline looks like, and the specific signs that warrant a clinical review.
• Magnesium Glycinate vs Citrate vs Threonate: Which Form Suits Which Goal? — Magnesium is sold in several forms, each bound to a different carrier. This article explains how glycinate, citrate and threonate differ, what research has looked at, and how to choose sensibly.
• Omega-3 Fatty Acids and Peptide Therapy: What Fish Oil Means for Inflammation Resolution and Repair Protocols — Omega-3 fatty acids are examined in inflammatory-signalling research, and this article reviews evidence and medication questions around peptides.
• ApoB vs LDL: Which Cholesterol Marker Matters More? — LDL cholesterol measures how much cholesterol is carried in the blood, while apolipoprotein B counts the particles carrying it. Research suggests particle number tracks cardiovascular risk more closely, which is why ApoB is increasingly included in longevity-focused blood panels.
• Psoriasis and Peptide Research: What the Evidence Shows About Immune Signalling and Skin Barrier Repair — Psoriasis is driven by an IL-23/IL-17 immune loop that accelerates keratinocyte turnover. Peptide research in skin repair and inflammation is mostly preclinical, and any use sits alongside, never in place of, specialist dermatological care.
• Electrolytes and Hydration in UAE Summers: What Sweat Actually Takes Out — Sweat carries sodium, potassium and magnesium as well as water. This article explains what research says about electrolyte losses in hot climates, when plain water is enough, and who should check with a doctor first.
• Peptides and Neurodegeneration: What Preclinical Research Shows About Cognitive Decline and Neuronal Protection — Neuroactive peptides such as Semax and Selank have been studied in cell and animal models of neuronal injury, but human evidence in neurodegenerative disease remains very limited. This article outlines the mechanisms under investigation, the translation gap, and why diagnosis and physician oversight come first.
• Peptides and Lung Health: What Research Shows About Respiratory Inflammation and Airway Repair — Some signalling peptides have been studied in preclinical and early clinical respiratory research, but none is an established lung treatment. This article reviews what the evidence suggests and why screening comes first.
• Migraine, CGRP and Peptide Therapy: What Neuropeptide Research Means for Protocol Design — Calcitonin gene-related peptide (CGRP) is a neuropeptide central to migraine biology, and CGRP-targeting medicines are now widely prescribed. This article explains what that means for patients considering additional peptide protocols, and where the evidence stops.
• PCOS and Peptide Research: What Insulin Resistance and Hormonal Signalling Mean for Protocol Design — Polycystic ovary syndrome is a metabolic and endocrine condition, not only a reproductive one. This article outlines what preclinical and early clinical research suggests about peptides in PCOS, and why screening and physician oversight come first.
• Eczema and Inflammatory Skin Conditions: What Peptide Research Shows About Barrier Repair and Immune Signalling — Atopic dermatitis involves a faulty skin barrier and overactive immune signalling. This article reviews what preclinical research suggests about GHK-Cu, KPV and BPC-157 in that context, and where the evidence stops.
• GLP-1 Weight Loss and Lean Mass: What the Research Shows About Muscle Preservation — Studies of GLP-1 medicines examine changes in lean tissue alongside body weight, and this article reviews measurement methods and trial limitations.
• Peptides and Spinal Disc Degeneration: What Preclinical Research Shows About Lower Back Pain — Intervertebral discs have a poor blood supply and limited capacity for self-repair, which makes degeneration a difficult target. This article reviews what preclinical research suggests about repair peptides and the disc, and where the evidence stops.
• Antibiotics and Peptide Therapy: What Fluoroquinolones and Other Antibiotic Courses Mean for Tendon Repair Protocols — Fluoroquinolone antibiotics carry a recognised warning for tendon injury, which makes them directly relevant to anyone using repair peptides. This article explains what is known, what remains uncertain, and why prescribers need to know about every antibiotic course.
• Fatty Liver (MASLD) and GH-Axis Peptides: What Tesamorelin Research Shows About Liver Fat — Metabolic dysfunction-associated steatotic liver disease is examined in growth-hormone-axis research, and this article reviews findings and evidence gaps.
• Post-Procedure Skin Recovery: What Peptide Research Shows After Laser, Microneedling and Chemical Peels — Laser resurfacing, microneedling and peels deliberately injure the skin to trigger repair. This article reviews what preclinical research suggests about peptides in that healing window, and why timing and physician oversight matter.
• Scar Tissue and Fibrosis: What Peptide Research Shows About Remodelling and Repair — Scar tissue forms when repair prioritises speed over structure, and fibrosis is that process left unresolved. Preclinical research suggests several peptides may influence the balance between inflammation, fibroblast activity and matrix remodelling.
• Antihistamines and Peptide Therapy: What Allergy Medication Means for Injection Reactions and Overnight Protocols — Antihistamines are among the most commonly used medications in the UAE, yet they interact with peptide protocols in two distinct ways: through sedation that can alter sleep and GH-axis timing, and through the masking of histamine-mediated injection-site reactions that clinicians rely on for safety review.
• Three Regulators, One Warning: Why Health Authorities Worldwide Are Targeting Unregulated Peptides — Three separate health authorities, including the Dutch inspectorate and Health Canada, issued warnings on grey-market peptides within months of each other.
• Post-Viral Fatigue and Peptide Research: What Is Known About Mitochondria, Immune Signalling and Recovery — Research on persistent fatigue after viral illness examines mitochondrial function and immune signalling, with important gaps in peptide-related evidence.
• The Contraceptive Pill and GH-Axis Peptides: What Oral Oestrogen Means for IGF-1 and Protocol Design — Oral oestrogen can affect IGF-1 through liver-related mechanisms, and this article reviews hormonal signalling and clinical assessment questions.
• ADHD Stimulant Medication and Neuroactive Peptides: What Methylphenidate and Amphetamines Mean for Semax and Selank Protocols — Stimulant medicines and neuroactive peptides act on overlapping dopaminergic and stress-signalling systems, with no robust interaction trials. This article explains what physicians review, how changes are sequenced, and who may need extra caution.
• Sleep Medications and GH-Axis Peptides: What Benzodiazepines and Z-Drugs Mean for Overnight Protocols — Benzodiazepines and z-drugs alter sleep architecture, including the slow-wave sleep during which most growth hormone is released. Research suggests this is relevant to how, and whether, GH-axis and sleep-related peptides are timed alongside them.
• Proton Pump Inhibitors and Peptide Therapy: What Acid-Suppressing Medication Means for Gut Repair Protocols — Proton pump inhibitors are among the most widely prescribed medicines in the world, and they change gastric chemistry, nutrient absorption and mucosal signalling. This article explains why a clinician needs to know about them before designing a repair or gut-focused peptide protocol.
• Corticosteroids and Peptide Therapy: What Steroid Medications Mean for GH-Axis and Repair Protocols — Corticosteroids prescribed for asthma, allergies, joint pain and autoimmune conditions can suppress growth-hormone secretion and slow tissue repair, so anyone on a peptide protocol should flag steroid use to their physician before starting or continuing treatment.
• Metformin and GH-Axis Peptides: What Diabetes Medication Means for Secretagogue Protocols — Metformin and GH-axis secretagogues affect glucose metabolism through opposite mechanisms, so combining them calls for closer monitoring rather than avoidance.
• SSRIs, Antidepressants and Peptide Therapy: What Serotonergic Medications Mean for Protocol Design — SSRIs and SNRIs affect serotonergic signalling, and this article examines peptide-related research and questions for clinician-led medication assessment.
• Skin Laxity After Rapid Weight Loss: What Peptide Research Shows About Elastin and Collagen Support — Skin changes after rapid weight reduction are a subject of collagen and elastin research, and this article examines the limits of peptide-related findings.
• Thymosin Beta-4 and Corneal Repair: What Ocular Surface Research Shows — Thymosin Beta-4, the parent peptide behind TB-500, has been studied for its role in corneal epithelial healing and ocular surface inflammation. This article reviews what the research shows and why the eye is a distinct repair environment from skin or tendon.
• Melatonin and GH-Axis Peptides: What Exogenous Melatonin Means for Secretagogue Timing — Melatonin and growth-hormone release are examined in sleep research, and this article reviews hormonal signalling without advising peptide schedules.
• Blood Pressure Medications and Peptide Therapy: What ACE Inhibitors, Beta-Blockers and Diuretics Mean for Your Protocol — ACE inhibitors, beta-blockers, calcium channel blockers and diuretics all intersect with peptide physiology in different ways, and a proper protocol accounts for each before dosing begins.
• Anticoagulants and Peptide Therapy: What Blood Thinners Mean for Repair Protocols — Patients on warfarin, DOACs or antiplatelet therapy face a different bruising and bleeding-risk profile with subcutaneous repair peptides, and protocols need to account for it. Here is what the interaction actually involves and how physician-led screening addresses it.
• NSAIDs, BPC-157 and TB-500: Research and Medication Review — NSAIDs influence inflammatory signalling, and this article reviews peptide-related research and questions for a clinician-led medication assessment.
• Peptides and Gum Tissue Repair: What Periodontal Research Shows — The mouth heals faster than almost any other tissue, partly thanks to peptides found naturally in saliva. This article reviews what preclinical research suggests about BPC-157, GHK-Cu and Thymosin Beta-4 in gum and oral tissue repair, and where the evidence stops.
• Shift Work and the GH Axis: How Rotating Schedules Reshape Peptide Protocol Timing — Chronic shift rotation fragments the slow-wave sleep that drives the body's largest growth hormone pulse, so GH-axis peptide protocols need to be timed to a worker's actual sleep window rather than a fixed clock time.
• UV Exposure and Photoageing: What Peptide Research Shows About Skin Repair in a High-Sun Climate — UV exposure drives collagen breakdown through a well-mapped biological cascade that early preclinical research on GHK-Cu and antioxidants is studying.
• Peptide Protocols and Vaccination: Timing and Immune Considerations — Routine vaccines such as flu, travel and booster jabs raise practical questions for patients on peptide therapy. This article explains how physicians think about timing, which peptide classes matter most, and why physicians sometimes advise a short pause.
• Airborne Dust and Dry Air: What UAE's Climate Means for Skin-Barrier Peptide Protocols — The UAE's dust exposure and air-conditioned dryness place unusual, cumulative stress on the skin barrier; research into copper and anti-inflammatory peptides offers early clues on how skin-focused repair protocols may need to account for this environment.
• Collagen Supplements and Prescription Peptides: Why 'Collagen Peptides' Are Not the Same Thing — Hydrolysed collagen powders are marketed as 'collagen peptides', but they are digested into amino acids and act through nutrition, not signalling. This article explains how they differ from prescription peptides such as GHK-Cu and BPC-157, and how a physician thinks about the two together.
• Statins and Peptide Therapy: What Cholesterol Medication Means for Your Protocol — Statins are among the most widely prescribed medications in the UAE, and many patients starting a peptide protocol are already taking one. Here is what the overlap between statins and growth-hormone-axis or repair peptides actually involves.
• Creatine and Peptide Therapy: How the Most-Studied Sports Supplement Interacts with Repair and GH-Axis Protocols — Creatine use raises questions about interpreting creatinine measurements, and this article examines supplement research and peptide care assessment.
• Intermittent Fasting and GH-Axis Peptides: How Fasting States Shape Secretagogue Timing — Fasting affects ghrelin and insulin signalling, and this article reviews growth-hormone-axis research without recommending peptide treatment schedules.
• Andropause and the Somatopause: How Age-Related Testosterone Decline Shapes GH-Axis Peptide Protocols in Men — Testosterone decline in ageing men interacts with the growth hormone axis in ways that influence how GH-axis peptide protocols are sequenced, dosed and monitored; this article reviews the physiology behind that overlap.
• Forged Certificates of Analysis: The Peptide Vendor Case Every Buyer Should Know — A peptide vendor case involved forged laboratory certificates, and this article examines why vendor-provided documents require independent verification.
• Peptide Therapy, Pregnancy and Breastfeeding: Why Protocols Are Paused and What the Evidence Gap Means — Pregnancy and breastfeeding raise important evidence gaps in peptide-related research, and clinical decisions require individual physician assessment.
• Menopause and the Somatopause: How Oestrogen Decline Reshapes GH-Axis Peptide Protocols — Growth hormone secretion declines around the menopause transition in a process researchers call the somatopause, and it changes how GH-axis peptide protocols are screened, dosed and monitored in perimenopausal and menopausal patients.
• Peptides and Peripheral Nerve Regeneration: What the Research Shows About Neuropathy and Nerve Repair — Peripheral nerves regenerate slowly and often incompletely after injury, compression or metabolic damage. This article reviews the preclinical research on BPC-157, GHK-Cu, thymosin beta-4 and GH-axis signalling in nerve repair, and explains how a physician assesses nerve-related cases.
• The Gut Microbiome and Peptide Therapy: How Intestinal Health Shapes Inflammation, Repair and Protocol Outcomes — The gut microbiome regulates systemic inflammation, nutrient absorption and immune signalling, all of which influence how repair and GH-axis peptides perform. This article reviews what preclinical and early human research suggests about the gut-peptide relationship and why intestinal health is now part of pre-protocol screening.
• Peptides and Hair Follicle Biology: What the Research Shows on Thinning and Regrowth — Hair thinning is usually a shift in the follicle's growth cycle rather than a loss of the follicle itself. This article reviews what preclinical and early clinical research suggests about GHK-Cu, thymosin beta-4 and GH-axis signalling in follicle biology, and how a physician approaches hair within a broader protocol.
• Peptides and Concussion: What Preclinical Research Shows About Mild Traumatic Brain Injury — Concussion triggers a cascade of inflammation, oxidative stress and disrupted blood flow that continues for days after impact. This article reviews what animal and early human research shows about BPC-157, Semax, Cerebrolysin-type peptides and GH-axis signalling in mild traumatic brain injury, and where the evidence stops.
• Sauna, Ice Baths and Peptide Therapy: How Heat and Cold Exposure Interact with GH-Axis and Repair Protocols — Sauna sessions and cold plunges are now standard features of UAE gyms and wellness clubs, and both change the physiology that peptide protocols act on. This article reviews what the research shows about heat and cold exposure, growth hormone release and tissue repair, and how timing matters when the two are combined.
• Caffeine and GH-Axis Peptides: How Coffee, Energy Drinks and Pre-Workout Stimulants Interact with Secretagogue Protocols — Caffeine influences sleep and hormonal signalling, and this article examines growth-hormone-axis research without advising peptide dosing schedules.
• Nicotine, Smoking and Peptide Therapy: How Tobacco and Vaping Affect Tissue Repair and GH Release — Nicotine constricts the microvasculature, blunts collagen synthesis and alters growth hormone signalling, all of which can work directly against repair and GH-axis peptide protocols. This article reviews what the research shows and how prescribers account for nicotine use in protocol design.
• Testosterone Replacement and GH-Axis Peptides: How TRT Interacts with Secretagogue Protocols — Testosterone and growth hormone share overlapping signalling pathways, which means men on TRT need protocol design that accounts for both axes. This article explains the interaction, the monitoring that matters, and why the two therapies should never be run in isolation from each other.
• Micronutrient Cofactors in Peptide Therapy: Why Zinc, Magnesium and B12 Status Shape GH-Axis and Repair Outcomes — Peptides signal, but the downstream work of hormone synthesis, collagen formation and cellular repair depends on enzyme cofactors. This article explains why zinc, magnesium and vitamin B12 status are checked before and during protocols, and what the evidence does and does not support.
• Peptides and Arthritis: What the Research Shows About Joint Inflammation, Cartilage and Pain — Osteoarthritis and inflammatory arthritis share two problems that peptide research examines: persistent low-grade inflammation and poor cartilage repair. This article reviews what preclinical and early clinical data suggest about BPC-157, TB-500, GHK-Cu, KPV and GH-axis peptides in joint health, and where the evidence stops.
• Obstructive Sleep Apnoea and the GH Axis: Why Undiagnosed OSA Can Blunt Secretagogue Protocols — Obstructive sleep apnoea fragments the slow-wave sleep in which most growth hormone is released, and research shows GH and IGF-1 are suppressed in untreated OSA. This article explains why OSA screening belongs in the workup before any GH-axis peptide protocol.
• Inflammatory Markers in Peptide Therapy: What hs-CRP, IL-6 and Ferritin Can and Cannot Tell You — Inflammatory blood markers are increasingly used to establish a baseline and track response during peptide protocols. This article explains what hs-CRP, IL-6 and ferritin measure, how they are interpreted, and where their limits lie.
• Exercise Timing and GH-Axis Peptides: How Training Interacts with Secretagogue Injection Windows — Exercise timing and growth-hormone release are examined in physiology research, and this article reviews peptide-related evidence without advising timing.
• Vitamin D Status and Peptide Therapy: Why the UAE's Sunshine Paradox Matters for Your Protocol — Vitamin D deficiency is widespread among UAE residents despite year-round sun, and low status is relevant to the bone, muscle and immune pathways that GH-axis, repair and immune peptides are studied for. This article explains the mechanisms and why 25-hydroxyvitamin D belongs on the pre-protocol panel.
• Peptides and Cardiovascular Health: What the Research Shows About Endothelial Function and Cardiac Tissue — Peptide studies examine blood vessels and cardiac tissue in experimental models, and this article reviews the evidence and its clinical limitations.
• Protein Intake, Amino Acids and Peptide Research — Protein intake and amino acid availability are relevant to tissue biology, and this article examines their relationship to peptide-related research.
• Alcohol and Peptide Therapy: How Ethanol Affects GH Release, Tissue Repair, and Protocol Outcomes — Alcohol suppresses nocturnal growth hormone release, slows collagen synthesis, and shifts sleep architecture, all of which overlap with the pathways most peptide protocols rely on. This article reviews what the research shows and how physicians factor drinking habits into protocol design.
• Kidney and Liver Function in Peptide Therapy: How Peptides Are Cleared and Why Renal and Hepatic Panels Matter — Most therapeutic peptides are broken down by enzymes in the blood and tissues, but the kidneys and liver still shape how long they circulate. This article explains peptide clearance and why renal and hepatic markers are part of responsible screening.
• Autoimmune Conditions and Peptide Therapy: Why Immune-Modulating Peptides Need Extra Screening — Several therapeutic peptides act directly on immune signalling, which is a factor physicians weigh when a patient has a history of autoimmune disease. This article explains which peptide classes raise the question, what a physician looks for, and why the answer is rarely a simple yes or no.
• Tendon and Ligament Healing: Why Connective Tissue Recovers Slowly and What Peptide Research Shows — Tendon and ligament repair involves connective tissue remodelling, and this article reviews preclinical peptide research and its limits in human care.
• Cancer History and GH-Axis Peptides: Why Oncological Screening Comes Before Any Protocol — A history of cancer raises clinical assessment questions around growth-hormone signalling, and this article reviews the evidence and its limitations.
• Thyroid Function and the GH Axis: Why Peptide Protocols Depend on Adequate Thyroid Hormone — Thyroid hormones and growth-hormone signalling interact in endocrine physiology, and this article examines research and clinical assessment questions.
• GH-Axis Peptides and Blood Glucose: Why Growth Hormone Secretagogues Can Shift Insulin Sensitivity — Growth hormone is a counter-regulatory hormone, so peptides that raise GH output can transiently reduce insulin sensitivity and lift fasting glucose. This article explains the mechanism, what the research shows, and how physician-led protocols monitor for it.
• What 6,441 Grey-Market Peptide Samples Revealed About Purity, Endotoxin and Price — An analysis of 6,441 grey-market peptide samples examined purity, contamination and price, and this article reviews the reported findings and limitations.
• Peptides and the Blood-Brain Barrier: Which Molecules Reach the Central Nervous System — Many peptides are discussed in terms of mood, sleep, focus and cognition, but most large molecules never enter brain tissue at all. This article explains what the blood-brain barrier is, the routes by which peptides cross it, and why a molecule can influence the brain without ever getting inside it.
• Digital Biomarkers and Peptide Therapy: What Wearable Data Can and Cannot Tell You — Wearable devices record sleep, heart rate and glucose trends, and this article reviews what those measurements can and cannot establish about health.
• Cortisol and the HPA Axis: How Chronic Stress Signalling Shapes Peptide Protocol Design — Cortisol is involved in the hypothalamic-pituitary-adrenal axis, and this article examines hormonal signalling and limits of peptide-related research.
• Peptides and Bone Health: What the Research Shows About Skeletal Remodelling — Bone remodelling is influenced by hormonal signalling, and this article reviews peptide-related studies and the gap between research and clinical practice.
• Sarcopenia and the GH Axis: What the Research Says About Age-Related Muscle Loss — Sarcopenia involves age-related loss of skeletal tissue and function, and this article reviews GH-axis research and limits of peptide-related evidence.
• Peptide Therapy Around Surgery: Disclosure, Washout and Review — Patients on peptide protocols are frequently unsure what to do when elective surgery is scheduled. This article explains why surgical teams need a full disclosure, how half-life shapes any washout period, and why resumption should be led by the operating surgeon.
• GLP-1 Receptor Agonists Are Peptides Too: Where Semaglutide Sits in the Wider Peptide Landscape — Semaglutide and tirzepatide are engineered peptide medicines with specific indications, and this article reviews research and regulatory distinctions.
• Peptides and Anti-Doping: WADA Status, Testing Windows, and What Competitive Athletes Should Disclose — Several widely discussed regenerative peptides, including BPC-157, TB-500 and growth hormone secretagogues, sit on the World Anti-Doping Agency Prohibited List under categories S0 and S2. This article explains how those categories work, why out-of-competition testing matters, and what a competing athlete should tell their prescriber.
• Peptide Therapy and the Female Hormonal Cycle: What Changes Protocol Design for Women — Most peptide research has been conducted in predominantly male cohorts, yet sex differences in hormone signalling, body composition and clearance shape how protocols are designed. This article looks at what clinicians weigh when prescribing peptide therapy for women.
• Peptide Immunogenicity: Why the Body Sometimes Forms Antibodies to Therapeutic Peptides — Any peptide introduced into the body can, in principle, be recognised by the immune system. This article explains what immunogenicity is, which molecular features raise or lower the risk, and why it shapes how protocols are designed and monitored.
• Frequent Flying and Peptide Therapy: Travel, Time Zones, and Protocol Continuity — Long-haul travel disrupts the physiological rhythms that peptide protocols are built around, and it raises practical questions about cold chain, documentation, and dosing across time zones. This article explains what changes when a patient on an active protocol flies regularly.
• Why Peptides Are Injected: Delivery Routes, Bioavailability, and What Survives Digestion — Peptide bioavailability varies with molecular structure and formulation, and this article reviews delivery-route research without advising administration.
• Peptide Protocols During Ramadan: Fasting Windows, Injection Timing, and Hydration — Ramadan changes when patients eat, train, sleep and hydrate, and each of those interacts with how a peptide protocol is timed. This article explains what typically shifts during the fasting month and why protocols are best reviewed in advance rather than mid-cycle.
• Peptide Interactions with Common Medications: What Your Prescriber Needs to Know — Peptide-related medication assessment considers pharmacology and patient context, and this article examines interaction questions and evidence gaps.
• Subcutaneous Injection Technique and Site Rotation Explained — Peptide protocols prescribed by a physician are typically delivered by subcutaneous injection, with technique and site rotation affecting absorption. Administration should follow the method and setting advised by the prescribing clinician.
• Peptide Half-Life and Pharmacokinetics: Why Dosing Frequency Is Built Around the Molecule — Peptides differ enormously in how long they persist in the body, from a few minutes to several days. This article explains half-life, clearance, and why pharmacokinetics is what actually determines when and how often a protocol is dosed.
• Peptide Receptor Sensitivity and Tachyphylaxis: Research Considerations — Receptor sensitivity and tachyphylaxis are studied in pharmacology, and this article examines those concepts without recommending peptide treatment cycles.
• BPC-157 in Dubai: Research and Regulatory Status — BPC-157 is a peptide investigated mainly in preclinical research, and this article reviews evidence limitations and regulatory questions in Dubai.
• Peptide Therapy in the UAE: What It Is, How It Works, and Where to Start — Peptide-related enquiries in the UAE involve scientific and regulatory questions, with assessment and treatment decisions belonging to licensed physicians.
• The Skin Regeneration Stack: How GHK-Cu, BPC-157, and KPV Are Studied Together — Skin ageing is driven by collagen loss, chronic low-grade inflammation, and slower repair signalling. This article examines how three peptides with distinct mechanisms are studied as a combined approach to dermal regeneration, and what physician oversight adds.
• Your First Peptide Consultation in Dubai: What to Expect — UAE Peptide Clinic coordinates patient enquiries as a brokerage, while independent licensed physicians make assessment and treatment decisions.
• Circadian Rhythm and Peptide Timing: Why the Body Clock Shapes Protocol Design — Circadian rhythms influence hormone release and cellular signalling, and this article reviews peptide-related research without advising treatment timing.
• NAD+ IV and Subcutaneous Delivery: What the Evidence Shows — NAD+ can be delivered intravenously or subcutaneously, and researchers compare the routes for pharmacokinetic differences, not clinical superiority. Oversight and route selection are discussed alongside the available evidence.
• Peptide Therapy in the Gulf Climate: Heat, Training Load, and Recovery in Active Professionals — Heat, humidity, and disrupted sleep change the physiological background against which any peptide protocol is assessed. This article looks at what research suggests about recovery in Gulf conditions and what clinicians should be monitoring through the summer months.
• BPC-157 and Athletes in Dubai: What the Research Shows — BPC-157 is discussed in sports-related preclinical research, and this article reviews evidence limitations without assuming clinical outcomes for athletes.
• The Wolverine Stack: BPC-157 and TB-500 Research — The Wolverine Stack is an informal name for BPC-157 and TB-500 used together, with evidence for the combination largely limited to preclinical research.
• MOTS-C in Dubai: The Mitochondrial Peptide Studied for Metabolic Health and Exercise Adaptation — MOTS-C is a mitochondrially-derived peptide discovered in 2015. Here is what the research says about its role in metabolic regulation and how independent physicians approach it in the UAE.
• The Longevity Stack: How Epitalon, NAD+, and MOTS-C Are Studied Together — Longevity protocols increasingly combine peptides that act on different layers of cellular ageing rather than relying on a single compound. This article examines the research behind pairing Epitalon, NAD+ and MOTS-C, and why sequencing and physician oversight matter.
• Tesamorelin and Body Composition: Evidence from Phase 3 Clinical Trials — Tesamorelin has Phase 3 randomised evidence, including a large trial published in a major medical journal, reviewed here with its studied uses. Clinical interpretation of that evidence is discussed alongside monitoring considerations.
• Cold-Chain Delivery Explained: How Peptides Stay Stable in the UAE Climate — Peptides are temperature-sensitive molecules that can degrade in transit long before a patient notices anything is wrong. This article explains what cold-chain delivery actually involves, why Gulf ambient conditions demand tighter tolerances, and what to check when a shipment arrives.
• The UAE Crackdown on Online Peptide Sellers: What It Means for Patients — In August 2026 the Emirates Drug Establishment moved against dozens of online peptide sellers and the influencers promoting them. Here is what was found, what UAE physicians said, and why peptide therapy belongs with a licensed prescriber.
• GHK-Cu: What the Research Says About This Copper Peptide and Skin Health — Fifty years of research has examined GHK-Cu in collagen synthesis, wound models and skin regeneration. A physician-led summary and how protocols are supervised in Dubai.
• Why Physician-Supervised Peptide Therapy Matters in the UAE — Peptide-related enquiries require clinical and regulatory assessment, and this article explains the role of independent licensed physicians in the UAE.
• Thymosin Alpha-1: A Review of Human Clinical Research — Thymosin Alpha-1 has been examined in human clinical research across specific indications, and this article reviews the scope and limits of that evidence.
• GHK-Cu in Dubai: Skin, Collagen and Hair Research — GHK-Cu is a copper-binding peptide examined in skin and hair research, and this article reviews the evidence without implying clinical outcomes.
• NAD+ and Ageing: What Randomised Clinical Trials Actually Show — Randomised, placebo-controlled trials of NAD+ precursors have produced measurable biochemical changes in several short-term studies. Long-term clinical outcomes and optimal dosing remain under active study.
• Longevity Medicine in Dubai: Where Peptide Research Fits — Dubai has a growing longevity medicine sector. This article reviews where peptide research fits within physician-supervised longevity medicine locally.
• DSIP, Epitalon and GH-Axis Peptides: What Sleep-Related Research Shows — Sleep is a period in which growth hormone release and cellular repair processes are studied together across several peptide research programmes. How DSIP, Epitalon and GH-axis compounds relate to sleep architecture remains an area of active study.
• BPC-157: What Peer-Reviewed Research Shows About This Pentadecapeptide — Peer-reviewed BPC-157 studies include systematic reviews of preclinical findings, and this article examines evidence limitations in human care.
• Thymosin Alpha-1, KPV and BPC-157: Immune Research — Thymosin Alpha-1, KPV and BPC-157 are discussed in immune-signalling research, but findings on individual compounds do not establish combined outcomes.
• Peptide Product Storage: Labelling and Clinical Oversight — Peptide product storage depends on formulation and labelling, and handling questions require guidance from the responsible clinician or pharmacist.
• BPC-157, TB-500 and GHK-Cu: A Peptide Combination Explained — Preclinical research suggests BPC-157, TB-500 and GHK-Cu act on different phases of the tissue repair cascade. This article explains the mechanistic rationale researchers discuss, and why the combination has not been tested in human trials.
• Senolytics vs Peptide Therapy: Two Approaches to Cellular Ageing Compared — Senolytic compounds and peptides are investigated in ageing research, and this article reviews their different mechanisms and limitations of the evidence.
• Fake Weight-Loss Pens Filled With Insulin: What the Case Reveals About Grey Market Risk — Counterfeit semaglutide pens seized in 16 countries, patients hospitalised in Austria after injecting what turned out to be insulin, and hundreds of fake pens pulled from the UK supply. What the global counterfeit wave teaches anyone tempted to buy injectables online.
• The Role of Blood Panels in Peptide Therapy: What Your Clinic Should Be Testing Before and During Your Protocol — Blood panels provide clinical measurements that require interpretation in context, and this article reviews their role in peptide-related assessment.
• BPC-157 Arginate (PDA): The Stable Form of the Gastric Peptide Studied for Tissue Repair — BPC-157 arginate is a form of the gastric pentadecapeptide discussed in preclinical research, and this article examines molecular and evidence questions.
• Epitalon: The Tetrapeptide Studied for Telomere Lengthening and Biological Age — Epitalon is a synthetic tetrapeptide derived from epithalamin that has attracted scientific interest for its effects on telomere length, telomerase activation, and longevity markers across multiple model organisms.
• Research Use Only Labels: Meaning and Regulatory Questions — Research use only labels describe a laboratory-use designation, not authorization for human treatment, and this article examines regulatory questions.
• What Independent Lab Tests Found Inside Grey Market Peptides — Independent laboratory testing of peptides sourced from online research chemical vendors has consistently revealed a troubling picture. These are documented findings from third-party analyses conducted on products that real people are injecting.
• Why a Stronger Effect Is Not Always Better: The Overdose Problem with Grey Market Peptides — Grey market peptides are often described as "more powerful" than pharmacy-grade alternatives. In many cases, this perception has a straightforward explanation: the product simply contains more active compound than its label states.
• Bacterial Endotoxin: A Contamination Risk in Unregulated Peptides — Bacterial endotoxin is a contamination risk in unregulated peptide products that standard purity testing does not reliably detect. It is not caught by routine HPLC analysis.
• How to Read a Certificate of Analysis — And What It Does Not Tell You — Most grey market peptide vendors publish a certificate of analysis alongside their products. It looks official. It reports purity at 98 or 99 per cent. For many buyers, it provides reassurance. It should not.
• GMP vs GLP: The Standard That Actually Matters for Your Peptide — GMP and GLP describe different quality frameworks, and this article explains their scope without treating either label as a guarantee of clinical outcomes.
• Over 455 Adverse Events: What the FDA Data on Compounded Peptides Reveals — The scale of the grey market peptide problem became visible in a way that was hard to ignore. The FDA issued more than 50 warning letters to manufacturers of compounded semaglutide and tirzepatide after receiving hundreds of adverse event reports. The lessons extend well beyond GLP-1s.
• DHA, MOHAP, EDE: Understanding the UAE Regulatory Framework for Peptide Therapy — DHA, MOHAP and EDE have distinct roles in UAE health regulation, and this article explains why licensing does not authorize every medical product.
• Peptide-Related Clinical Assessment: Monitoring and Uncertainty — Clinical assessment of a peptide-related intervention considers individual circumstances, research limitations and monitoring without predicting outcomes.
• Bryan Johnson's Blueprint Protocol in 2026: The Peptide Science Behind It — This article reviews the peptide science behind Bryan Johnson's Blueprint protocol, a documented longevity regimen revised significantly in 2026.
• Epigenetic Reprogramming and Peptides: Where the Science Is in 2026 — The idea that markers of biological age might be partially reset in cells has moved from science fiction into peer-reviewed journals. Epigenetic reprogramming is at the centre of that research, and peptides are sometimes mentioned in the same conversation.
• GH Pulse Timing and Peptide Injections: The Research — Growth hormone is released in pulses rather than continuously, and this article reviews the physiology and limits of peptide-related timing research.
• Longevity Medicine in the UAE: Research and Regulatory Context — Longevity medicine is discussed in the UAE within a changing research and regulatory context, and this article reviews questions around clinical oversight.
• Stacking Peptides: The Case For and Against Combinations — Peptide stacking, combining two or more compounds in a single protocol, is a widely discussed and often misunderstood area of peptide research. Evidence for specific combinations varies and is often limited.
• BPC-157: What It Is and What the Research Has Examined — BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid peptide derived from a protective protein sequence found in human gastric juice. It has been studied mainly in animal models in relation to tissue repair, gut health and injury recovery.
• TB-500: What the Research Shows on Tissue Repair — TB-500 is a synthetic analogue of Thymosin Beta-4, naturally involved in actin polymerisation, cell migration, and wound healing. It has been studied for systemic rather than local activity, with research examining repair across multiple tissue types.
• GHK-Cu: Copper Peptide, Skin Regeneration and the Science Behind It — GHK-Cu is a naturally occurring copper-binding tripeptide examined in experimental studies of tissue biology, with limitations in human clinical evidence.
• IGF-1 LR3: Growth Factor Signalling, Anabolism, and Clinical Considerations — IGF-1 LR3 is a modified analogue of insulin-like growth factor 1, and this article examines its molecular features and limitations of research findings.
• Ipamorelin: How This GH Secretagogue Is Studied — Ipamorelin is a synthetic pentapeptide and selective agonist of the growth hormone secretagogue receptor. Among GH-stimulating peptides, it is notable for what it does not do: it does not meaningfully elevate cortisol, prolactin, or appetite at therapeutic doses.
• MOTS-C: The Mitochondrial-Derived Peptide Explained — MOTS-C is a peptide encoded within the mitochondrial genome, studied as a regulator that may translate cellular metabolic status into systemic signals. Its role in human metabolism remains an area of ongoing research.
• NAD+: The Coenzyme in Longevity Research Explained — NAD+ is not strictly a peptide but a coenzyme, and its age-related decline is studied as one contributor among several to cellular changes. Research into supplementation is ongoing and findings remain preliminary.
• Selank: What Neuroactive Peptide Research Shows — Selank is a synthetic peptide examined in neuroactive and immune-signalling research, and this article reviews findings and limitations of the evidence.
• Semax: The Research on Cognition and Neuroprotection — Semax is a synthetic analogue of the ACTH fragment 4-7, registered in Russia for neurological indications. Its primary studied effects relate to cognitive function, neuroprotection, and the regulation of brain-derived neurotrophic factor.
• Tesamorelin: A GHRH Analogue and What the Research Shows — Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone, examined in clinical research for a specific disease-related indication.
• Thymosin Alpha-1: Molecular Features and Clinical Research — Thymosin Alpha-1 is a naturally occurring 28-amino-acid peptide examined in immune-related research, with findings that depend on the studied indication.
• Bremelanotide (PT-141): The Melanocortin Mechanism Explained — Bremelanotide, known as PT-141, is a melanocortin receptor agonist studied for its action on brain melanocortin receptors linked to arousal. Research has focused on central nervous system mechanisms rather than confirmed outcomes.
• Epitalon: Telomerase, Longevity, and Four Decades of Research — Epitalon is a synthetic tetrapeptide derived from a pineal gland extract. It has attracted scientific attention because laboratory studies reported effects on telomerase, the enzyme that maintains the protective end caps on chromosomes known as telomeres.
• CJC-1295 and Ipamorelin: The Combination Explained — CJC-1295 and Ipamorelin are examined in growth-hormone-axis research, and this article reviews their receptor mechanisms and combination evidence limits.
• Kisspeptin: Hormonal Signalling and the HPG Axis — Kisspeptin is a signalling peptide involved in the hypothalamic-pituitary-gonadal axis, and this article reviews research into its receptor pathways.
• DSIP: Delta Sleep-Inducing Peptide and the Science of Deep Sleep Architecture — DSIP was named after early research reporting increased delta wave sleep. Decades of research have examined that finding, with mixed and mostly small human studies. Here is what the research has looked at.
• AOD-9604: A Peptide Fragment Derived from Growth Hormone — AOD-9604 is a synthetic fragment of human growth hormone investigated in metabolic research, and this article reviews the limits of the evidence.
• KPV: The Anti-Inflammatory Tripeptide and Its Role in Gut Health — KPV is a tripeptide derived from alpha-MSH and investigated in inflammatory-signalling research, with limits when applying findings to human care.
• Sermorelin: The Original GHRH Analogue Explained — Sermorelin is a 29-amino-acid analogue of growth-hormone-releasing hormone, and this article reviews its molecular features and clinical research context.
• CJC-1295: Long-Acting GHRH Analogue — Clinical Profile and How It Differs from Mod GRF — CJC-1295 is a modified GHRH analogue designed for extended duration of action. Its drug affinity complex (DAC) modification allows it to bind albumin in the bloodstream, extending its half-life from minutes to several days.
• Sermorelin, GHRP-6 and GHRP-2: Receptor Mechanisms and Research — Sermorelin, GHRP-6 and GHRP-2 act through different receptor pathways, and this article reviews their pharmacology and the limits of combination evidence.
• Tesamorelin, Mod GRF 1-29 and Ipamorelin Explained — This combination brings together three structurally distinct compounds acting through two separate receptor families. Here is what is known about the mechanism, and why it sits firmly within physician oversight.
• The Wolverine Stack: How TB-500 and BPC-157 Are Studied — The Wolverine Stack is an informal name for TB-500 and BPC-157 used together, with evidence for the combination largely limited to preclinical research.
• TB-500, BPC-157 and GHK-Cu: A Peptide Combination Explained — TB-500, BPC-157 and GHK-Cu are sometimes discussed together in peptide research, though the combination has not been tested in human trials. Individual mechanisms do not establish combined efficacy.